US Stock Movements | Biopharmaceutical company Evommune (EVMN.US) debuts on the US stock market with a stock price surge of over 15%

According to the Wisdom Finance APP, Evommune (EVMN.US) has debuted on the US stock market. As of the time of writing, the stock has risen more than 15%, reaching $18.38, with an IPO price of $16. Evommune is a clinical-stage biopharmaceutical company with a mission to treat "immune-mediated chronic inflammatory diseases" through innovative therapies. These diseases include chronic urticaria, atopic dermatitis, and other conditions related to mast cells/inflammation.